Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03191383
Recruitment Status : Withdrawn (Study was canceled due to instability of the PreF antigen during manufacturing. No safety concern has been identified in past or ongoing studies.)
First Posted : June 19, 2017
Last Update Posted : October 15, 2018
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Tracking Information
First Submitted Date  ICMJE June 15, 2017
First Posted Date  ICMJE June 19, 2017
Last Update Posted Date October 15, 2018
Actual Study Start Date  ICMJE July 11, 2017
Actual Primary Completion Date July 14, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 20, 2017)
  • Number of subjects with solicited local adverse events (AEs) [ Time Frame: During a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
  • Number of subjects with solicited general AEs [ Time Frame: During the 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited general symptoms are fatigue, fever [defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination
  • Number of subjects with unsolicited AEs [ Time Frame: During a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days) ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
  • Number of subjects with haematological abnormalities [ Time Frame: At Day 0 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
  • Number of subjects with haematological abnormalities [ Time Frame: At Day 7 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cell count [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
  • Number of subjects with biochemical abnormalities [ Time Frame: At Day 0 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
  • Number of subjects with biochemical abnormalities [ Time Frame: At Day 7 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
  • Number of subjects with any serious adverse events (SAEs) [ Time Frame: From study start (Day 0) up to 6 months after delivery ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Number of infant subjects with any SAEs [ Time Frame: From birth up to 6 months after birth ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Number of subjects with pregnancy outcomes [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.
  • Number of subjects with pregnancy-related AEs of specific interest [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioamnionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.
  • Number of infant subjects with AEs of specific interest [ Time Frame: From birth up to 6 months after birth ]
    Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.
Original Primary Outcome Measures  ICMJE
 (submitted: June 15, 2017)
  • Number of subjects with solicited local adverse events (AEs) [ Time Frame: During a 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited local symptoms are pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevents normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
  • Number of subjects with solicited general AEs [ Time Frame: During the 7-day follow-up period after vaccination (i.e. the day of vaccination and 6 subsequent days) ]
    Assessed solicited general symptoms are fatigue, fever [defined as oral/axillary/tympanic route temperature equal to or above 37.5 degrees Celsius (°C) or ≥ 38 °C for rectal route], gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevents normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination
  • Number of subjects with unsolicited AEs [ Time Frame: During a 30-day follow-up period after vaccination (i.e. the day of vaccination and 29 subsequent days) ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevents normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
  • Number of subjects with haematological abnormalities [ Time Frame: At Day 0 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cells [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
  • Number of subjects with haematological abnormalities [ Time Frame: At Day 7 ]
    Haematological laboratory abnormalities include haemoglobin level, white blood cells [WBC], lymphocyte, neutrophil, eosinophil, platelet count, red blood cell count and mean corpuscular volume.
  • Number of subjects with biochemical abnormalities [ Time Frame: At Day 0 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
  • Number of subjects with biochemical abnormalities [ Time Frame: At Day 7 ]
    Biochemical laboratory abnormalities include alanine amino-transferase [ALT], aspartate amino-transferase [AST], creatinine and blood urea nitrogen.
  • Number of subjects with any serious adverse events (SAEs) [ Time Frame: From study start (Day 0) up to 6 months after delivery ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Number of infant subjects with any SAEs [ Time Frame: From birth up to 6 months after birth ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Number of subjects with pregnancy outcomes [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy outcomes include live birth with no congenital anomalies, live birth with congenital anomalies, foetal death/still birth with no congenital anomalies, foetal death/still birth with congenital anomalies, elective/therapeutic termination with no congenital anomalies and elective/therapeutic termination with congenital anomalies.
  • Number of subjects with pregnancy-related AEs of specific interest [ Time Frame: From study start (Day 0) up to delivery ]
    Pregnancy-related adverse events of specific interest include: gestational diabetes, gestational liver disease (including obstetric cholestasis and acute fatty liver of pregnancy), chorioammionitis, labour protraction and arrest disorders, maternal sepsis, pregnancy-related hypertension, preterm premature rupture of membranes, premature labour, intrauterine growth restriction/poor foetal growth, pre-eclampsia and eclampsia, vaginal or intrauterine haemorrhage, medical conditions necessitating early delivery (induced labour or urgent C-section) (placenta abruption, uterine infection, oligohydramnios, etc), maternal death.
  • Number of infant subjects with AEs of specific interest [ Time Frame: From birth up to 6 months after birth ]
    Infant-related AEs of specific interest include preterm birth, neonatal death, low birth weight and/or small for gestational age, neonatal sepsis, foetal/perinatal distress or asphyxia, failure to thrive/growth deficiency, congenital anomalies and neurodevelopmental delay.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 15, 2017)
  • Number of infant subjects with SAEs [ Time Frame: From birth and up to study end (Year 2) ]
    SAEs are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
  • Number of infant subjects with AEs potentially related to maternal vaccination [ Time Frame: From birth up to study end (Year 2) ]
    Related infant AEs = AEs occurring in the infant assessed by the investigator as potentially related to the vaccination of the mother.
  • Number of infant subjects with neuro-developmental delays [ Time Frame: At Year 1 and Year 2 ]
    Infant subjects with Ages and Stages Questionnaires version 3 (ASQ-3) scores in the grey and black zones for any of the 5 developmental areas or domains (communication, gross motor skills, fine motor skills, problem solving and personal-social) : Grey zone (i.e. Monitoring zone) score means that the child's score falls ≥ 1 but <2 standard deviations below the mean score in any developmental area. Black zone (i.e. Referral zone) score means that the child's score falls below the cut-off (i.e. 2 standard deviations below the mean score) in any developmental area. Infant subjects scoring in the black zone in any of the 5 domains of the ASQ-3 will be referred for formal neurological evaluation
  • Number of infant subjects referred for formal neurological evaluation [ Time Frame: At Year 1 and Year 2 ]
    Neuro-developmental formal evaluation will be performed, for infants with ASQ3 black zone scores, using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
  • Number of infant subjects with confirmed developmental delay [ Time Frame: At Year 1 and Year 2 ]
    Infants confirmed as having neuro-developmental delay following formal evaluation using the Bayley Scale for Infant Development, Version III (BSID-III) or an equivalent.
  • Neutralizing antibody titres against RSV-A, for all vaccinated mothers [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery ]
    Titres will be expressed as geometric mean titres (GMTs)
  • Neutralizing antibody titres against RSV-B, for all vaccinated mothers [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post vaccination and at delivery ]
    Titres will be expressed as geometric mean titres (GMTs)
  • Palivizumab competing antibody (PCA) concentrations, for all vaccinated mothers. [ Time Frame: At pre-vaccination (Day 0), Day 30 and Day 60 post-vaccination and at delivery ]
    Concentrations will be expressed as geometric mean concentrations (GMCs)
  • Neutralizing antibody titres against RSV-A, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
  • Neutralizing antibody titres against RSV-B, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Titres will be expressed as geometric mean titres (GMTs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
  • PCA concentrations, for all infants born to vaccinated mothers [ Time Frame: At birth, at Month 3 and at Month 6 ]
    Concentrations will be expressed as geometric mean concentrations (GMCs). Infants will be allocated to one of the 2 defined sub-cohorts (Month 3 or Month 6) and have the blood sample for immunogenicity obtained at the corresponding sub-cohort timepoint.
  • Number of infant subjects with lower respiratory tract infection (LRTI), severe LRTI and respiratory tract infection (RTI) with parental concern (according to the case definitions) associated with a respiratory syncytial virus (RSV) infection [ Time Frame: From birth up to study end (Year 2) ]
    Occurrence of RSV-LRTI, severe RSV-LRTI, RSV-RTI with parental concern
  • Number of subjects (vaccinated mothers) with medically-attended (MA) RTI associated with an RSV infection [ Time Frame: From Day 0 up to Month 6 post delivery ]
    Occurrence of RSV associated MA-RTI. A MA-RTI is defined as a visit of the mother to a health care professional for any respiratory symptom, including cough, sputum production and difficulty breathing
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Official Title  ICMJE An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Brief Summary The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Respiratory Syncytial Virus Infections
Intervention  ICMJE
  • Biological: RSV vaccine (GSK3003891A) formulation 1
    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
  • Biological: RSV vaccine (GSK3003891A) formulation 2
    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
  • Biological: RSV vaccine (GSK3003891A) formulation 3
    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
  • Drug: Placebo (Formulation buffer S9b)
    Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study Arms  ICMJE
  • Experimental: GSK3003891A vaccine formulation 1 mother Group
    Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
    Intervention: Biological: RSV vaccine (GSK3003891A) formulation 1
  • Experimental: GSK3003891A vaccine formulation 2 mother Group
    Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
    Intervention: Biological: RSV vaccine (GSK3003891A) formulation 2
  • Experimental: GSK3003891A vaccine formulation 3 mother Group
    Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
    Intervention: Biological: RSV vaccine (GSK3003891A) formulation 3
  • Placebo Comparator: Control group
    Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
    Intervention: Drug: Placebo (Formulation buffer S9b)
  • No Intervention: GSK3003891A vaccine formulation 1 infant Group
    Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
  • No Intervention: GSK3003891A vaccine formulation 2 infant Group
    Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
  • No Intervention: GSK3003891A vaccine formulation 3 infant Group
    Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
  • No Intervention: Control infant Group
    Infants born to mothers who received a single placebo injection
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: August 3, 2017)
0
Original Estimated Enrollment  ICMJE
 (submitted: June 15, 2017)
1114
Actual Study Completion Date  ICMJE July 14, 2017
Actual Primary Completion Date July 14, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent for study participation of the mother obtained from the mother or the mother and father, as applicable by local law, prior to performance of any study specific procedure.
  • Written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or legally acceptable representative [LAR] prior to performance of any study specific procedure.
  • Subjects between, and including, 18 and 40 years of age at the time of the first study visit.
  • Pregnant females > 24 weeks of gestation at the time of screening and at 28 0/7 to 33 6/7 weeks of gestation at the time of vaccination, as established by ultrasound examination and last menstrual period date.
  • Healthy pregnant females as established by medical history and clinical examination before entering into the study.
  • Pregnant females not at high risk for complications, as determined by the obstetrical risk assessment form.
  • No significant foetal findings observed during a second or third trimester ultrasound.
  • Subjects who are willing to provide cord blood.
  • Subjects who do not plan to give their child for adoption or place the child in care.

Inclusion Criteria infants:

• Re-signed written informed consent for study participation of the infant obtained from the infant's mother and/or father, as applicable by local law, or LAR.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before vaccination , or planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before vaccination and ending at delivery with the exception of seasonal influenza vaccine and diphtheria, tetanus, pertussis/tetanus, diphtheria, pertussis [dTpa/Tdap] vaccine as part of standard of care which may be administered ≥ 15 days before or after study vaccination.
  • Chronic administration of systemic immunosuppressants or other immune-modifying drugs, as well as administration of long-acting immune-modifying drugs during the period starting 6 months prior to study vaccination, or planned administration up to delivery. Topical steroids are allowed. Inhaled steroids are allowed up to the limit of ≤500 µg/day for beclomethasone or fluticasone, or ≤ 800 µg/day for budesonide.
  • Administration of immunoglobulins (with the exception of prophylactic anti-Rh0D immune globulin) and/or any blood products during the period starting 3 months before study vaccination or planned administration during the study period.
  • Previous experimental vaccination against RSV.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Low lying placenta during the current pregnancy, unless there is documented sonographic evidence that the placenta has moved up prior to enrolment.
  • Any abnormal finding observed in nuchal translucency scan, serum testing and any other prenatal tests, if conducted.
  • Incompetent cervix or cerclage during the current pregnancy.
  • Having received medical treatment for suspected preterm delivery during the current pregnancy.
  • Prior preterm delivery or having ongoing intervention in current pregnancy to prevent preterm delivery.
  • Prior stillbirth or neonatal death, or ≥ 2 spontaneous abortions.
  • Personal history of major congenital anomalies or early onset of eclampsia/pre-eclampsia in previous pregnancy.
  • 1st degree relatives family history of major congenital anomalies and/ or hereditary immunodeficiency.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Hemodynamically significant cardiac disorders.
  • Gestational diabetes as determined by glucose challenge/tolerance test conducted after 20 weeks of gestation or as per local recommendations of the country, requiring intervention other than diet for control. In countries where glucose challenge/tolerance testing is not routinely performed in all pregnant women, should the screening urinalysis test show presence of glucose in urine, a glucose challenge/tolerance test should be performed and results should be available prior to enrolment, in order to exclude gestational diabetes prior to subject receiving the study vaccine.
  • History of gestational diabetes in previous pregnancy(ies).
  • Hypertension during the current pregnancy as defined below or if any antihypertensive medication is being provided, or history of hypertension requiring antihypertensive medication:

Hypertension during current pregnancy is defined as:

  • a blood pressure systolic > 140 and/or diastolic 90 mmHg, documented in at least 2 separate measurements .

    • Current obstetric cholestasis or history of obstetric cholestasis.
    • Asthma and/or chronic obstructive pulmonary disease [COPD] if the subject is receiving treatment with chronic systemic glucocorticoids at any dose or inhaled glucocorticoids > 500 µg/day of beclomethasone or fluticasone, or > 800 µg/day of budesonide.
    • Significant neuro-psychiatric illness deemed likely to interfere with protocol compliance, safety reporting or receipt of pre-natal care, or requiring treatment with psychotropic drugs.
    • Diagnosed with Zika virus infection or suspected to have or have had Zika virus infection during the current pregnancy.
    • Known HIV infection, as assessed by local standard of care serologic tests conducted during the current pregnancy and prior to enrolment.
    • Known or suspected Hepatitis B virus [HBV] or Hepatitis C virus [HCV] infection.
    • Known infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Rubella, cytomegalovirus [CMV] or primary Herpes Simplex.
    • Known foetal anomalies in the current pregnancy.
    • Any clinically significant haematological and/or biochemical laboratory abnormality.
  • Subjects with haematological/ biochemical values out of normal range which are expected to be temporary may be re-screened at a later date within the allowed time interval.

    • Acute disease and/or fever within 3 days prior to enrolment .

  • Fever is defined as temperature ≥ 37.5°C/99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C/100.4°F for rectal route.
  • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • For subjects with acute disease and/ or fever at the time of enrolment, Visit 1 may be scheduled at a later date within the allowed time interval and gestational age.

    • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
    • Hypersensitivity to latex.
    • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
    • History of drug or alcohol abuse within the past 2 years.
    • Any condition which, in the investigator's opinion, would increase the risks of study participation to the unborn infant.
    • Planned move to a location that will prohibit participating in the trial until study end.

Exclusion Criteria infants:

• Any condition which, in the investigator's opinion, would increase the risks of study participation to the infant.

Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 40 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Finland,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03191383
Other Study ID Numbers  ICMJE 204810
2016-002733-30 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.
Responsible Party GlaxoSmithKline
Study Sponsor  ICMJE GlaxoSmithKline
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: GSK Clinical Trials GlaxoSmithKline
PRS Account GlaxoSmithKline
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP